 Wendy Kohrt
Concepts (655)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 43 | 2021 | 432 | 7.020 |
Why?
| | Exercise | 66 | 2022 | 1644 | 5.830 |
Why?
| | Body Composition | 51 | 2022 | 590 | 4.620 |
Why?
| | Bone and Bones | 16 | 2021 | 278 | 3.610 |
Why?
| | Parathyroid Hormone | 9 | 2021 | 96 | 3.430 |
Why?
| | Postmenopause | 30 | 2020 | 303 | 3.420 |
Why?
| | Menopause | 13 | 2022 | 271 | 3.150 |
Why?
| | Estrogens | 20 | 2020 | 312 | 3.110 |
Why?
| | Bone Resorption | 7 | 2022 | 73 | 2.780 |
Why?
| | Estradiol | 17 | 2021 | 455 | 2.690 |
Why?
| | Calcium | 7 | 2021 | 1104 | 2.440 |
Why?
| | Premenopause | 11 | 2020 | 106 | 2.350 |
Why?
| | Exercise Therapy | 18 | 2022 | 350 | 2.220 |
Why?
| | Gonadotropin-Releasing Hormone | 8 | 2018 | 188 | 2.210 |
Why?
| | Estrogen Replacement Therapy | 15 | 2019 | 116 | 2.130 |
Why?
| | Walking | 11 | 2021 | 422 | 2.020 |
Why?
| | Energy Metabolism | 14 | 2022 | 731 | 2.000 |
Why?
| | Parkinson Disease | 15 | 2024 | 345 | 1.950 |
Why?
| | Collagen Type I | 12 | 2021 | 108 | 1.870 |
Why?
| | Endothelium, Vascular | 10 | 2022 | 843 | 1.770 |
Why?
| | Estrogens, Conjugated (USP) | 8 | 2017 | 34 | 1.740 |
Why?
| | Calcium, Dietary | 7 | 2017 | 55 | 1.700 |
Why?
| | Middle Aged | 122 | 2022 | 26719 | 1.660 |
Why?
| | Resistance Training | 7 | 2018 | 113 | 1.530 |
Why?
| | Aged | 107 | 2022 | 19061 | 1.490 |
Why?
| | Osteoporosis, Postmenopausal | 9 | 2019 | 36 | 1.490 |
Why?
| | Dehydroepiandrosterone | 5 | 2018 | 49 | 1.490 |
Why?
| | Insulin | 26 | 2022 | 2076 | 1.460 |
Why?
| | Adipose Tissue | 24 | 2022 | 539 | 1.450 |
Why?
| | Female | 171 | 2024 | 59466 | 1.450 |
Why?
| | Lumbar Vertebrae | 10 | 2021 | 209 | 1.450 |
Why?
| | Femur Neck | 8 | 2020 | 59 | 1.450 |
Why?
| | Aging | 28 | 2022 | 1618 | 1.370 |
Why?
| | Peptides | 11 | 2021 | 848 | 1.310 |
Why?
| | Ovary | 3 | 2020 | 191 | 1.310 |
Why?
| | Humans | 225 | 2024 | 114624 | 1.300 |
Why?
| | Homeostasis | 7 | 2019 | 573 | 1.290 |
Why?
| | Bicycling | 9 | 2014 | 86 | 1.270 |
Why?
| | Hormone Replacement Therapy | 9 | 2018 | 77 | 1.260 |
Why?
| | Lipolysis | 6 | 2014 | 39 | 1.220 |
Why?
| | Glucose | 12 | 2018 | 896 | 1.190 |
Why?
| | Arthroplasty, Replacement, Knee | 9 | 2017 | 246 | 1.150 |
Why?
| | Obesity | 19 | 2015 | 2507 | 1.140 |
Why?
| | Muscle, Skeletal | 17 | 2020 | 1472 | 1.140 |
Why?
| | Oxygen Consumption | 31 | 2012 | 588 | 1.120 |
Why?
| | Cardiovascular Diseases | 11 | 2022 | 1727 | 1.070 |
Why?
| | Sleep | 7 | 2022 | 631 | 1.070 |
Why?
| | Sleep Deprivation | 5 | 2022 | 166 | 1.040 |
Why?
| | Adiposity | 5 | 2018 | 457 | 1.030 |
Why?
| | Absorptiometry, Photon | 17 | 2021 | 224 | 1.000 |
Why?
| | Physical Endurance | 19 | 2015 | 232 | 0.990 |
Why?
| | Adult | 85 | 2022 | 30528 | 0.960 |
Why?
| | Motor Activity | 11 | 2015 | 640 | 0.960 |
Why?
| | Male | 125 | 2024 | 55555 | 0.940 |
Why?
| | Weight Loss | 9 | 2020 | 641 | 0.910 |
Why?
| | Quadriceps Muscle | 5 | 2017 | 104 | 0.910 |
Why?
| | Muscle Strength | 8 | 2018 | 270 | 0.870 |
Why?
| | Vascular Stiffness | 5 | 2018 | 407 | 0.860 |
Why?
| | Dehydroepiandrosterone Sulfate | 4 | 2013 | 45 | 0.840 |
Why?
| | Sweating | 2 | 2019 | 23 | 0.840 |
Why?
| | Vasodilation | 8 | 2020 | 419 | 0.830 |
Why?
| | Insulin Resistance | 11 | 2017 | 1072 | 0.830 |
Why?
| | Hypothalamo-Hypophyseal System | 3 | 2018 | 164 | 0.810 |
Why?
| | Glycerol | 8 | 2013 | 84 | 0.800 |
Why?
| | Adipocytes | 5 | 2022 | 188 | 0.800 |
Why?
| | Pituitary-Adrenal System | 2 | 2018 | 130 | 0.790 |
Why?
| | Double-Blind Method | 12 | 2018 | 1660 | 0.780 |
Why?
| | Electric Stimulation Therapy | 2 | 2012 | 56 | 0.760 |
Why?
| | Follicle Stimulating Hormone | 5 | 2021 | 216 | 0.750 |
Why?
| | Raloxifene Hydrochloride | 3 | 2017 | 13 | 0.730 |
Why?
| | Frail Elderly | 5 | 2013 | 106 | 0.730 |
Why?
| | Weight-Bearing | 7 | 2017 | 165 | 0.730 |
Why?
| | Trigger Points | 2 | 2018 | 14 | 0.720 |
Why?
| | Subcutaneous Fat | 3 | 2014 | 70 | 0.720 |
Why?
| | Exercise Test | 18 | 2024 | 544 | 0.700 |
Why?
| | Skin | 4 | 2019 | 655 | 0.690 |
Why?
| | Osteoarthritis, Knee | 6 | 2018 | 213 | 0.690 |
Why?
| | Bone Remodeling | 5 | 2022 | 65 | 0.680 |
Why?
| | Sex Factors | 9 | 2020 | 1715 | 0.680 |
Why?
| | Activities of Daily Living | 7 | 2020 | 349 | 0.660 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2021 | 299 | 0.650 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 2018 | 67 | 0.650 |
Why?
| | Adaptation, Physiological | 4 | 2012 | 483 | 0.630 |
Why?
| | Lactic Acid | 7 | 2018 | 275 | 0.630 |
Why?
| | Headache Disorders | 1 | 2018 | 12 | 0.620 |
Why?
| | Tension-Type Headache | 1 | 2018 | 6 | 0.620 |
Why?
| | Physical Fitness | 9 | 2014 | 179 | 0.620 |
Why?
| | Biomarkers | 15 | 2022 | 3408 | 0.610 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2022 | 1214 | 0.600 |
Why?
| | Weight Gain | 3 | 2011 | 453 | 0.600 |
Why?
| | Massage | 1 | 2018 | 42 | 0.600 |
Why?
| | Hot Temperature | 1 | 2019 | 302 | 0.580 |
Why?
| | Blood Glucose | 21 | 2013 | 1819 | 0.580 |
Why?
| | Regional Blood Flow | 3 | 2018 | 424 | 0.580 |
Why?
| | Immunoglobulin G | 3 | 2021 | 770 | 0.580 |
Why?
| | Heart Rate | 19 | 2024 | 709 | 0.570 |
Why?
| | Osteoporosis | 9 | 2017 | 226 | 0.570 |
Why?
| | Leptin | 7 | 2022 | 210 | 0.560 |
Why?
| | Health | 3 | 2017 | 74 | 0.550 |
Why?
| | Abdomen | 9 | 2005 | 99 | 0.550 |
Why?
| | Brachial Artery | 7 | 2020 | 176 | 0.540 |
Why?
| | Leuprolide | 2 | 2017 | 19 | 0.540 |
Why?
| | Dietary Supplements | 2 | 2017 | 460 | 0.530 |
Why?
| | Testosterone | 6 | 2022 | 343 | 0.520 |
Why?
| | Ibuprofen | 2 | 2021 | 75 | 0.520 |
Why?
| | Aged, 80 and over | 22 | 2019 | 6344 | 0.520 |
Why?
| | Osteogenesis | 5 | 2020 | 183 | 0.510 |
Why?
| | Glucose Clamp Technique | 13 | 2014 | 181 | 0.500 |
Why?
| | Severity of Illness Index | 11 | 2018 | 2537 | 0.500 |
Why?
| | Antibodies | 1 | 2017 | 371 | 0.490 |
Why?
| | Young Adult | 19 | 2022 | 10455 | 0.490 |
Why?
| | Glucose Tolerance Test | 11 | 2013 | 343 | 0.490 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2017 | 26 | 0.480 |
Why?
| | Medroxyprogesterone | 2 | 2007 | 10 | 0.480 |
Why?
| | Health Status | 4 | 2020 | 722 | 0.470 |
Why?
| | Gonadal Steroid Hormones | 4 | 2021 | 124 | 0.470 |
Why?
| | Perimenopause | 4 | 2022 | 61 | 0.460 |
Why?
| | Medroxyprogesterone Acetate | 4 | 2003 | 28 | 0.450 |
Why?
| | Thigh | 3 | 2010 | 53 | 0.440 |
Why?
| | Saliva | 2 | 2005 | 187 | 0.440 |
Why?
| | Running | 9 | 2015 | 207 | 0.440 |
Why?
| | Quality of Life | 8 | 2022 | 2353 | 0.430 |
Why?
| | Deuterium | 6 | 2019 | 79 | 0.420 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 140 | 0.420 |
Why?
| | Treatment Outcome | 18 | 2022 | 9084 | 0.420 |
Why?
| | Cognition Disorders | 2 | 2015 | 476 | 0.410 |
Why?
| | Cognition | 3 | 2013 | 988 | 0.410 |
Why?
| | Body Weight | 13 | 2022 | 868 | 0.410 |
Why?
| | Sweat | 4 | 2019 | 38 | 0.410 |
Why?
| | Femur | 5 | 2018 | 191 | 0.400 |
Why?
| | Hydrocortisone | 3 | 2018 | 267 | 0.390 |
Why?
| | Heart-Assist Devices | 3 | 2023 | 485 | 0.390 |
Why?
| | Hormone Antagonists | 1 | 2011 | 33 | 0.380 |
Why?
| | Baroreflex | 2 | 2022 | 54 | 0.370 |
Why?
| | HIV Infections | 8 | 2020 | 2469 | 0.370 |
Why?
| | Analysis of Variance | 11 | 2018 | 1226 | 0.370 |
Why?
| | Physical Education and Training | 14 | 1996 | 62 | 0.370 |
Why?
| | Procollagen | 3 | 2020 | 19 | 0.360 |
Why?
| | Osteocalcin | 5 | 2022 | 34 | 0.360 |
Why?
| | Lipids | 5 | 2013 | 580 | 0.360 |
Why?
| | Carotid Arteries | 5 | 2018 | 180 | 0.350 |
Why?
| | Sympathetic Nervous System | 1 | 2011 | 171 | 0.350 |
Why?
| | Disability Evaluation | 5 | 2013 | 271 | 0.340 |
Why?
| | Vasodilator Agents | 1 | 2012 | 302 | 0.340 |
Why?
| | Acetaminophen | 1 | 2012 | 238 | 0.340 |
Why?
| | Gravitation | 1 | 2009 | 20 | 0.340 |
Why?
| | Menstrual Cycle | 2 | 2013 | 108 | 0.340 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 77 | 0.340 |
Why?
| | Heart Failure | 4 | 2024 | 1945 | 0.330 |
Why?
| | Cross-Sectional Studies | 14 | 2022 | 4405 | 0.330 |
Why?
| | Osteoarthritis | 2 | 2015 | 171 | 0.320 |
Why?
| | Exercise Tolerance | 3 | 2015 | 213 | 0.320 |
Why?
| | Hip | 5 | 2012 | 46 | 0.320 |
Why?
| | Adolescent | 14 | 2022 | 17831 | 0.320 |
Why?
| | Prospective Studies | 16 | 2019 | 6217 | 0.320 |
Why?
| | Range of Motion, Articular | 7 | 2017 | 350 | 0.310 |
Why?
| | Dyslipidemias | 1 | 2010 | 154 | 0.310 |
Why?
| | Circadian Rhythm | 4 | 2020 | 354 | 0.310 |
Why?
| | Progesterone Congeners | 3 | 2003 | 14 | 0.310 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1139 | 0.310 |
Why?
| | Physical Exertion | 6 | 2001 | 209 | 0.300 |
Why?
| | Urine | 3 | 2004 | 54 | 0.300 |
Why?
| | Glucose Intolerance | 4 | 1999 | 136 | 0.300 |
Why?
| | Pain Measurement | 6 | 2018 | 444 | 0.300 |
Why?
| | Sports | 5 | 2020 | 187 | 0.290 |
Why?
| | High-Intensity Interval Training | 2 | 2018 | 18 | 0.290 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2019 | 3244 | 0.290 |
Why?
| | Pain Threshold | 3 | 2018 | 67 | 0.290 |
Why?
| | Body Mass Index | 9 | 2019 | 1956 | 0.280 |
Why?
| | Alkaline Phosphatase | 2 | 2021 | 143 | 0.280 |
Why?
| | Fractures, Bone | 4 | 2016 | 367 | 0.270 |
Why?
| | Body Water | 2 | 2004 | 19 | 0.270 |
Why?
| | Peptide Fragments | 3 | 2020 | 665 | 0.270 |
Why?
| | Postural Balance | 6 | 2015 | 183 | 0.270 |
Why?
| | Hypogonadism | 3 | 2015 | 75 | 0.270 |
Why?
| | Area Under Curve | 5 | 2013 | 274 | 0.260 |
Why?
| | Risk Factors | 11 | 2019 | 8628 | 0.260 |
Why?
| | Microdialysis | 6 | 2012 | 49 | 0.250 |
Why?
| | Heart Ventricles | 2 | 2020 | 712 | 0.250 |
Why?
| | Blood Coagulation | 1 | 2007 | 218 | 0.250 |
Why?
| | Water | 2 | 2019 | 396 | 0.250 |
Why?
| | Cardiac Output | 5 | 2023 | 143 | 0.250 |
Why?
| | Radioisotope Dilution Technique | 2 | 2004 | 13 | 0.250 |
Why?
| | Cholesterol | 4 | 2011 | 367 | 0.250 |
Why?
| | Time Factors | 14 | 2019 | 6112 | 0.240 |
Why?
| | Bone Marrow Cells | 3 | 2021 | 267 | 0.240 |
Why?
| | Oxidative Stress | 4 | 2022 | 1076 | 0.240 |
Why?
| | Basal Metabolism | 1 | 2005 | 46 | 0.240 |
Why?
| | Recovery of Function | 6 | 2017 | 574 | 0.240 |
Why?
| | Triglycerides | 3 | 2011 | 467 | 0.230 |
Why?
| | Serum | 1 | 2004 | 57 | 0.230 |
Why?
| | Blood Pressure | 10 | 2022 | 1538 | 0.230 |
Why?
| | Regression Analysis | 6 | 2011 | 944 | 0.230 |
Why?
| | HIV-1 | 4 | 2013 | 768 | 0.230 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2024 | 27 | 0.220 |
Why?
| | Diet | 7 | 2019 | 1080 | 0.220 |
Why?
| | Placebos | 4 | 2011 | 197 | 0.220 |
Why?
| | Sports Medicine | 1 | 2004 | 104 | 0.210 |
Why?
| | Knee Joint | 6 | 2017 | 323 | 0.210 |
Why?
| | Arginine | 4 | 2017 | 238 | 0.210 |
Why?
| | Intermittent Claudication | 2 | 2015 | 108 | 0.200 |
Why?
| | Circadian Clocks | 2 | 2019 | 42 | 0.200 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2013 | 286 | 0.200 |
Why?
| | Torque | 2 | 2012 | 66 | 0.200 |
Why?
| | Ultrasonography | 7 | 2018 | 633 | 0.190 |
Why?
| | Ventricular Function, Right | 2 | 2020 | 250 | 0.190 |
Why?
| | Weight Reduction Programs | 2 | 2014 | 94 | 0.190 |
Why?
| | Vitamin D | 3 | 2020 | 341 | 0.190 |
Why?
| | Cross-Over Studies | 3 | 2014 | 440 | 0.190 |
Why?
| | Oxygen Isotopes | 2 | 2019 | 19 | 0.190 |
Why?
| | Sex Characteristics | 9 | 2020 | 640 | 0.190 |
Why?
| | Proteins | 5 | 1998 | 908 | 0.190 |
Why?
| | Cholesterol, HDL | 4 | 2011 | 183 | 0.190 |
Why?
| | Hip Joint | 3 | 2019 | 126 | 0.180 |
Why?
| | Intestinal Absorption | 1 | 2001 | 93 | 0.180 |
Why?
| | Dexamethasone | 2 | 2018 | 317 | 0.180 |
Why?
| | Postprandial Period | 1 | 2001 | 87 | 0.180 |
Why?
| | Pressoreceptors | 1 | 2021 | 18 | 0.180 |
Why?
| | Glycosylation | 2 | 2021 | 130 | 0.180 |
Why?
| | Superficial Back Muscles | 2 | 2018 | 13 | 0.180 |
Why?
| | Physical Conditioning, Animal | 4 | 2019 | 194 | 0.180 |
Why?
| | Polysaccharides | 2 | 2021 | 78 | 0.180 |
Why?
| | Muscle Proteins | 3 | 2019 | 210 | 0.180 |
Why?
| | Interleukin-6 | 2 | 2022 | 676 | 0.180 |
Why?
| | Pilot Projects | 6 | 2020 | 1372 | 0.180 |
Why?
| | Pulmonary Gas Exchange | 5 | 2017 | 117 | 0.180 |
Why?
| | Surveys and Questionnaires | 8 | 2019 | 4620 | 0.180 |
Why?
| | Lactates | 8 | 2012 | 79 | 0.180 |
Why?
| | Oxidation-Reduction | 5 | 2020 | 923 | 0.180 |
Why?
| | Luteal Phase | 2 | 2014 | 41 | 0.170 |
Why?
| | Carbohydrate Metabolism | 3 | 1998 | 48 | 0.170 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2023 | 358 | 0.170 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 20 | 0.170 |
Why?
| | Animals | 21 | 2022 | 31695 | 0.170 |
Why?
| | Reference Values | 6 | 2013 | 742 | 0.170 |
Why?
| | Patient Compliance | 4 | 2015 | 524 | 0.160 |
Why?
| | Coronary Disease | 2 | 2001 | 348 | 0.160 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 206 | 0.160 |
Why?
| | Geographic Atrophy | 1 | 2019 | 49 | 0.160 |
Why?
| | Myocardial Contraction | 1 | 2020 | 313 | 0.160 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 37 | 0.160 |
Why?
| | Cholesterol, LDL | 4 | 2011 | 307 | 0.160 |
Why?
| | Health Behavior | 1 | 2004 | 704 | 0.160 |
Why?
| | Women's Health | 3 | 2020 | 271 | 0.160 |
Why?
| | Diet, Reducing | 1 | 1999 | 76 | 0.160 |
Why?
| | Cardiorespiratory Fitness | 1 | 2019 | 35 | 0.160 |
Why?
| | Calcium Channels, L-Type | 1 | 2019 | 107 | 0.160 |
Why?
| | Cold Temperature | 1 | 2019 | 126 | 0.160 |
Why?
| | Adipose Tissue, White | 1 | 2018 | 27 | 0.160 |
Why?
| | Acidosis | 1 | 2019 | 88 | 0.160 |
Why?
| | Proof of Concept Study | 1 | 2018 | 45 | 0.150 |
Why?
| | Homocysteine | 1 | 2019 | 136 | 0.150 |
Why?
| | Extracellular Fluid | 1 | 2018 | 30 | 0.150 |
Why?
| | Case-Control Studies | 6 | 2019 | 3003 | 0.150 |
Why?
| | Compliance | 2 | 2018 | 46 | 0.150 |
Why?
| | Cortisone | 1 | 2018 | 8 | 0.150 |
Why?
| | Adipose Tissue, Brown | 1 | 2018 | 43 | 0.150 |
Why?
| | Swimming | 2 | 1989 | 44 | 0.150 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2019 | 185 | 0.150 |
Why?
| | Ions | 1 | 2018 | 59 | 0.150 |
Why?
| | Cysteine | 1 | 2019 | 171 | 0.150 |
Why?
| | Osteoarthritis, Hip | 1 | 2018 | 39 | 0.150 |
Why?
| | Cancellous Bone | 1 | 2017 | 20 | 0.150 |
Why?
| | Macular Degeneration | 1 | 2019 | 152 | 0.150 |
Why?
| | Obesity, Abdominal | 2 | 2017 | 37 | 0.150 |
Why?
| | Physical Therapy Modalities | 2 | 2012 | 264 | 0.150 |
Why?
| | omega-N-Methylarginine | 1 | 1997 | 26 | 0.150 |
Why?
| | Cardiovascular Physiological Phenomena | 3 | 2015 | 40 | 0.150 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2018 | 128 | 0.140 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 217 | 0.140 |
Why?
| | Rest | 2 | 1997 | 103 | 0.140 |
Why?
| | Integrin beta1 | 1 | 2017 | 16 | 0.140 |
Why?
| | Thermogenesis | 1 | 2017 | 37 | 0.140 |
Why?
| | Isotope Labeling | 1 | 2017 | 69 | 0.140 |
Why?
| | Galactose | 1 | 2017 | 20 | 0.140 |
Why?
| | Peripheral Arterial Disease | 2 | 2015 | 380 | 0.140 |
Why?
| | Growth Hormone | 1 | 1997 | 103 | 0.140 |
Why?
| | Age Factors | 6 | 2011 | 2894 | 0.140 |
Why?
| | Lipid Metabolism | 3 | 1998 | 444 | 0.140 |
Why?
| | Forearm | 1 | 1997 | 112 | 0.140 |
Why?
| | Luteinizing Hormone | 2 | 2015 | 169 | 0.140 |
Why?
| | Electromyography | 2 | 2016 | 326 | 0.140 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2018 | 117 | 0.140 |
Why?
| | Hypokinesia | 1 | 2016 | 7 | 0.140 |
Why?
| | Healthy Volunteers | 2 | 2017 | 197 | 0.140 |
Why?
| | Stroke Volume | 6 | 2023 | 504 | 0.130 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 41 | 0.130 |
Why?
| | Osteoporotic Fractures | 1 | 2017 | 56 | 0.130 |
Why?
| | Pelvic Bones | 1 | 2018 | 126 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2019 | 230 | 0.130 |
Why?
| | Energy Intake | 5 | 2013 | 427 | 0.130 |
Why?
| | Food, Fortified | 1 | 2016 | 36 | 0.130 |
Why?
| | Administration, Cutaneous | 3 | 2015 | 117 | 0.130 |
Why?
| | Pain | 1 | 2001 | 705 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2019 | 2094 | 0.130 |
Why?
| | Adipocytes, White | 1 | 2015 | 17 | 0.130 |
Why?
| | Gonadotropins | 1 | 2015 | 37 | 0.130 |
Why?
| | Predictive Value of Tests | 4 | 2015 | 1796 | 0.130 |
Why?
| | Precision Medicine | 1 | 2019 | 336 | 0.130 |
Why?
| | Metabolomics | 1 | 2020 | 521 | 0.120 |
Why?
| | Mice | 7 | 2022 | 14860 | 0.120 |
Why?
| | Nitric Oxide | 2 | 2017 | 823 | 0.120 |
Why?
| | Aging, Premature | 2 | 2013 | 11 | 0.120 |
Why?
| | Muscle Strength Dynamometer | 2 | 2012 | 21 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 2279 | 0.120 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 666 | 0.120 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 931 | 0.120 |
Why?
| | Stem Cells | 2 | 2017 | 545 | 0.120 |
Why?
| | Injections, Intravenous | 2 | 2006 | 198 | 0.120 |
Why?
| | Accidental Falls | 2 | 2017 | 150 | 0.120 |
Why?
| | Wrist Joint | 1 | 1995 | 59 | 0.120 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2012 | 154 | 0.120 |
Why?
| | Muscles | 7 | 2013 | 320 | 0.120 |
Why?
| | Mass Spectrometry | 1 | 2017 | 633 | 0.120 |
Why?
| | Linear Models | 2 | 2008 | 768 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2387 | 0.110 |
Why?
| | Bone Density Conservation Agents | 1 | 2014 | 62 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 1842 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2018 | 4411 | 0.110 |
Why?
| | Spine | 1 | 1995 | 136 | 0.110 |
Why?
| | Neck Pain | 1 | 2013 | 22 | 0.110 |
Why?
| | Etanercept | 1 | 2013 | 51 | 0.110 |
Why?
| | Catecholamines | 1 | 1993 | 94 | 0.110 |
Why?
| | Radiography | 2 | 2012 | 812 | 0.110 |
Why?
| | Health Status Indicators | 2 | 2011 | 156 | 0.110 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 122 | 0.110 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 207 | 0.110 |
Why?
| | Community Health Services | 1 | 2015 | 212 | 0.110 |
Why?
| | C-Reactive Protein | 2 | 2022 | 362 | 0.110 |
Why?
| | Microfluidics | 1 | 2013 | 45 | 0.110 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 305 | 0.110 |
Why?
| | Hematopoietic Stem Cells | 3 | 2022 | 343 | 0.110 |
Why?
| | Mathematical Concepts | 1 | 2013 | 24 | 0.100 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2013 | 48 | 0.100 |
Why?
| | Acupressure | 1 | 2012 | 4 | 0.100 |
Why?
| | Hunger | 1 | 2013 | 37 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 951 | 0.100 |
Why?
| | Posture | 1 | 1993 | 152 | 0.100 |
Why?
| | Carbon Isotopes | 2 | 2006 | 111 | 0.100 |
Why?
| | Steroids | 1 | 2013 | 144 | 0.100 |
Why?
| | Neuropsychological Tests | 2 | 2015 | 927 | 0.100 |
Why?
| | Femoral Neck Fractures | 1 | 2012 | 22 | 0.100 |
Why?
| | Myofascial Pain Syndromes | 1 | 2012 | 13 | 0.100 |
Why?
| | Hemodynamics | 4 | 2023 | 1012 | 0.100 |
Why?
| | Incidence | 3 | 2019 | 2311 | 0.100 |
Why?
| | Research Design | 2 | 2019 | 928 | 0.100 |
Why?
| | Sarcopenia | 1 | 2013 | 63 | 0.100 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 54 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2012 | 45 | 0.100 |
Why?
| | Gait | 4 | 2015 | 249 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 106 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2015 | 224 | 0.100 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 4689 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 1999 | 1008 | 0.100 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 347 | 0.100 |
Why?
| | HIV Seropositivity | 1 | 2012 | 109 | 0.100 |
Why?
| | Meals | 1 | 2013 | 104 | 0.100 |
Why?
| | Headache | 1 | 2012 | 132 | 0.100 |
Why?
| | Spinal Fractures | 1 | 2012 | 75 | 0.090 |
Why?
| | Oxytocics | 1 | 2011 | 15 | 0.090 |
Why?
| | Muscle Fatigue | 1 | 2012 | 94 | 0.090 |
Why?
| | Athletes | 1 | 2014 | 328 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 5 | 2001 | 151 | 0.090 |
Why?
| | Perception | 2 | 2013 | 311 | 0.090 |
Why?
| | Cartilage, Articular | 1 | 2015 | 289 | 0.090 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 217 | 0.090 |
Why?
| | Kinetics | 5 | 2003 | 1551 | 0.090 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1121 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 411 | 0.090 |
Why?
| | Dinoprostone | 1 | 2011 | 184 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 493 | 0.090 |
Why?
| | Cohort Studies | 2 | 2012 | 4894 | 0.090 |
Why?
| | Hyperinsulinism | 2 | 2003 | 103 | 0.090 |
Why?
| | Depression | 1 | 2018 | 1133 | 0.090 |
Why?
| | Single-Blind Method | 3 | 2016 | 258 | 0.090 |
Why?
| | Parity | 1 | 2010 | 98 | 0.090 |
Why?
| | Chronic Pain | 1 | 2013 | 210 | 0.090 |
Why?
| | Bayes Theorem | 2 | 2022 | 329 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 668 | 0.080 |
Why?
| | Contraceptive Agents | 1 | 2010 | 54 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2013 | 959 | 0.080 |
Why?
| | Androgens | 2 | 2017 | 167 | 0.080 |
Why?
| | Carbon Dioxide | 2 | 2010 | 218 | 0.080 |
Why?
| | Antiparkinson Agents | 2 | 2022 | 26 | 0.080 |
Why?
| | Advance Care Planning | 1 | 2012 | 197 | 0.080 |
Why?
| | Efficiency | 1 | 1989 | 84 | 0.080 |
Why?
| | Bone Diseases, Metabolic | 2 | 2019 | 53 | 0.080 |
Why?
| | Respiration | 4 | 2015 | 179 | 0.080 |
Why?
| | Executive Function | 1 | 2013 | 379 | 0.080 |
Why?
| | Muscle Contraction | 1 | 2011 | 389 | 0.080 |
Why?
| | Mechanotransduction, Cellular | 1 | 2009 | 97 | 0.080 |
Why?
| | Calcium Citrate | 1 | 2008 | 1 | 0.080 |
Why?
| | Statistics as Topic | 1 | 2009 | 292 | 0.080 |
Why?
| | Ovariectomy | 3 | 2019 | 116 | 0.080 |
Why?
| | Spectrum Analysis | 2 | 2019 | 81 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 718 | 0.080 |
Why?
| | Cytokines | 1 | 2015 | 1840 | 0.070 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 467 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2005 | 1691 | 0.070 |
Why?
| | Low Back Pain | 1 | 2008 | 95 | 0.070 |
Why?
| | Cell Differentiation | 3 | 2021 | 1700 | 0.070 |
Why?
| | Leg | 3 | 2002 | 225 | 0.070 |
Why?
| | Norepinephrine | 2 | 2021 | 201 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1313 | 0.070 |
Why?
| | Carrier Proteins | 2 | 2005 | 695 | 0.070 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1430 | 0.070 |
Why?
| | Electric Stimulation | 1 | 2007 | 250 | 0.070 |
Why?
| | Life Style | 2 | 2008 | 430 | 0.070 |
Why?
| | Risk Reduction Behavior | 1 | 2008 | 201 | 0.070 |
Why?
| | Densitometry | 2 | 1998 | 29 | 0.060 |
Why?
| | Dietary Fats | 3 | 2013 | 287 | 0.060 |
Why?
| | Radioimmunoassay | 1 | 2005 | 162 | 0.060 |
Why?
| | Buttocks | 1 | 2005 | 10 | 0.060 |
Why?
| | Follicular Phase | 1 | 2005 | 36 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 192 | 0.060 |
Why?
| | Nutritional Status | 2 | 2019 | 287 | 0.060 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 197 | 0.060 |
Why?
| | Colorado | 4 | 2019 | 4099 | 0.060 |
Why?
| | Cell Lineage | 2 | 2017 | 309 | 0.060 |
Why?
| | Calorimetry, Indirect | 2 | 2017 | 69 | 0.060 |
Why?
| | Logistic Models | 2 | 2019 | 1840 | 0.060 |
Why?
| | Administration, Oral | 2 | 2018 | 728 | 0.060 |
Why?
| | Disease Progression | 1 | 2010 | 2380 | 0.050 |
Why?
| | Plethysmography | 2 | 2022 | 103 | 0.050 |
Why?
| | Endometrium | 1 | 2003 | 60 | 0.050 |
Why?
| | Models, Animal | 1 | 2004 | 344 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2015 | 385 | 0.050 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 35 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 257 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 82 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 41 | 0.050 |
Why?
| | Skinfold Thickness | 2 | 1992 | 49 | 0.050 |
Why?
| | Preoperative Period | 2 | 2014 | 103 | 0.050 |
Why?
| | Diphtheria Toxin | 1 | 2022 | 51 | 0.050 |
Why?
| | Knee | 2 | 1997 | 51 | 0.050 |
Why?
| | Rats | 7 | 2000 | 4958 | 0.050 |
Why?
| | Food Deprivation | 2 | 2000 | 24 | 0.050 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 106 | 0.050 |
Why?
| | Lipoproteins | 2 | 2000 | 159 | 0.050 |
Why?
| | Eating | 2 | 2001 | 344 | 0.050 |
Why?
| | Osteocytes | 1 | 2001 | 22 | 0.050 |
Why?
| | Signal Transduction | 2 | 2021 | 4509 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 248 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1211 | 0.050 |
Why?
| | Postoperative Period | 2 | 2014 | 289 | 0.050 |
Why?
| | Movement | 2 | 2014 | 244 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 105 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2002 | 121 | 0.050 |
Why?
| | Kidney | 2 | 1998 | 1188 | 0.050 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 10 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2005 | 532 | 0.050 |
Why?
| | Tibia | 2 | 2019 | 166 | 0.050 |
Why?
| | Stress, Mechanical | 2 | 2001 | 445 | 0.050 |
Why?
| | Child Development | 1 | 1985 | 385 | 0.040 |
Why?
| | Adiponectin | 1 | 2022 | 213 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 56 | 0.040 |
Why?
| | Musculoskeletal Physiological Phenomena | 1 | 2000 | 8 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2015 | 1947 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2022 | 387 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 158 | 0.040 |
Why?
| | Fasting | 1 | 2001 | 240 | 0.040 |
Why?
| | Electric Conductivity | 1 | 2019 | 88 | 0.040 |
Why?
| | Body Constitution | 1 | 1999 | 47 | 0.040 |
Why?
| | Blood Circulation | 1 | 1999 | 35 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2019 | 12542 | 0.040 |
Why?
| | Electrocardiography | 2 | 2020 | 560 | 0.040 |
Why?
| | Orchiectomy | 1 | 2019 | 57 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 95 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 87 | 0.040 |
Why?
| | Feasibility Studies | 2 | 2015 | 739 | 0.040 |
Why?
| | Muscle Development | 1 | 2000 | 98 | 0.040 |
Why?
| | Anthropometry | 2 | 2017 | 182 | 0.040 |
Why?
| | Longevity | 1 | 2020 | 137 | 0.040 |
Why?
| | Radius | 1 | 2019 | 33 | 0.040 |
Why?
| | Attitude | 1 | 2001 | 229 | 0.040 |
Why?
| | Physician's Role | 1 | 2001 | 197 | 0.040 |
Why?
| | Actigraphy | 1 | 2019 | 74 | 0.040 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 27 | 0.040 |
Why?
| | Socioeconomic Factors | 2 | 2013 | 1077 | 0.040 |
Why?
| | Mental Health | 2 | 2015 | 562 | 0.040 |
Why?
| | Isometric Contraction | 2 | 2010 | 155 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 195 | 0.040 |
Why?
| | Pregnancy | 1 | 2010 | 5517 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 530 | 0.040 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 43 | 0.040 |
Why?
| | North Carolina | 1 | 2018 | 97 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 1989 | 3039 | 0.040 |
Why?
| | Administration, Topical | 1 | 2018 | 138 | 0.040 |
Why?
| | Conservative Treatment | 1 | 2018 | 29 | 0.040 |
Why?
| | Ventricular Remodeling | 1 | 2000 | 226 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 121 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2019 | 125 | 0.040 |
Why?
| | Psychometrics | 1 | 2001 | 608 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 367 | 0.040 |
Why?
| | Hamstring Muscles | 1 | 2017 | 13 | 0.040 |
Why?
| | Nephrectomy | 1 | 1998 | 150 | 0.040 |
Why?
| | Goserelin | 1 | 2017 | 8 | 0.040 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 19 | 0.040 |
Why?
| | Blood | 2 | 1995 | 96 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 534 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 1997 | 90 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 49 | 0.030 |
Why?
| | Joints | 1 | 1997 | 84 | 0.030 |
Why?
| | Adipogenesis | 1 | 2017 | 42 | 0.030 |
Why?
| | Fibrin | 1 | 2017 | 65 | 0.030 |
Why?
| | Cell Size | 1 | 1996 | 80 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 73 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 213 | 0.030 |
Why?
| | Heart | 1 | 2020 | 612 | 0.030 |
Why?
| | Affect | 1 | 2018 | 246 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 1998 | 243 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2017 | 126 | 0.030 |
Why?
| | Monosaccharide Transport Proteins | 1 | 1996 | 45 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 50 | 0.030 |
Why?
| | Glycogen | 1 | 1996 | 51 | 0.030 |
Why?
| | Capillaries | 1 | 1996 | 91 | 0.030 |
Why?
| | Fatty Acids | 1 | 1998 | 381 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2001 | 442 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2635 | 0.030 |
Why?
| | Mental Status Schedule | 1 | 2015 | 33 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 19 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 167 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 275 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 696 | 0.030 |
Why?
| | Calibration | 1 | 1995 | 125 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 599 | 0.030 |
Why?
| | Muscular Atrophy | 1 | 1995 | 78 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 68 | 0.030 |
Why?
| | Neurophysiology | 1 | 2015 | 13 | 0.030 |
Why?
| | Databases, Bibliographic | 1 | 2015 | 29 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2007 | 2762 | 0.030 |
Why?
| | Arthrometry, Articular | 1 | 2014 | 9 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2018 | 478 | 0.030 |
Why?
| | United States | 1 | 2010 | 12176 | 0.030 |
Why?
| | Models, Biological | 2 | 1999 | 1620 | 0.030 |
Why?
| | Progesterone | 1 | 2015 | 232 | 0.030 |
Why?
| | Cholesterol Esters | 1 | 1993 | 9 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2015 | 224 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 2014 | 110 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2249 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 38 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2013 | 46 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 22 | 0.030 |
Why?
| | Comorbidity | 1 | 1998 | 1448 | 0.030 |
Why?
| | Citrates | 1 | 1993 | 43 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 60 | 0.030 |
Why?
| | Anaerobic Threshold | 1 | 1992 | 22 | 0.030 |
Why?
| | Appetite | 1 | 2013 | 52 | 0.030 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 162 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 66 | 0.030 |
Why?
| | Epinephrine | 1 | 1993 | 163 | 0.030 |
Why?
| | Upper Extremity | 1 | 2013 | 84 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2012 | 84 | 0.020 |
Why?
| | Registries | 1 | 2019 | 1767 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 342 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2013 | 138 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1056 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2013 | 122 | 0.020 |
Why?
| | Somatomedins | 1 | 1991 | 28 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 520 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 610 | 0.020 |
Why?
| | Glycoproteins | 1 | 1993 | 304 | 0.020 |
Why?
| | Apolipoproteins B | 1 | 1991 | 41 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 305 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 176 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 530 | 0.020 |
Why?
| | Disabled Persons | 1 | 2013 | 133 | 0.020 |
Why?
| | Viral Load | 1 | 2013 | 405 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1131 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 256 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 50 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2012 | 219 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 430 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 822 | 0.020 |
Why?
| | Liver | 2 | 1996 | 1634 | 0.020 |
Why?
| | Hyperglycemia | 2 | 1991 | 291 | 0.020 |
Why?
| | Glycogen Storage Disease Type V | 1 | 1990 | 1 | 0.020 |
Why?
| | Physical Phenomena | 1 | 2010 | 12 | 0.020 |
Why?
| | Macrophages | 1 | 2017 | 1261 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 316 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2319 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 471 | 0.020 |
Why?
| | Blood Vessels | 1 | 1991 | 180 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 288 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 953 | 0.020 |
Why?
| | Spirometry | 1 | 2010 | 224 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 3 | 2000 | 2218 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 3881 | 0.020 |
Why?
| | Body Temperature | 1 | 2010 | 208 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 2967 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1037 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 993 | 0.020 |
Why?
| | Child | 2 | 2004 | 18404 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2013 | 3531 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 522 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 687 | 0.020 |
Why?
| | Iodine Radioisotopes | 2 | 1998 | 125 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2008 | 222 | 0.020 |
Why?
| | Neoplasms | 1 | 2001 | 2097 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 1987 | 28 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 58 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3328 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 159 | 0.020 |
Why?
| | DNA | 1 | 2012 | 1352 | 0.020 |
Why?
| | Shoes | 1 | 1985 | 21 | 0.020 |
Why?
| | Aerobiosis | 1 | 1985 | 20 | 0.020 |
Why?
| | Orthotic Devices | 1 | 1985 | 28 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2008 | 680 | 0.010 |
Why?
| | Body Height | 1 | 1985 | 180 | 0.010 |
Why?
| | Endometrial Hyperplasia | 1 | 2003 | 10 | 0.010 |
Why?
| | Uterine Hemorrhage | 1 | 2003 | 34 | 0.010 |
Why?
| | Inflammation | 1 | 2013 | 2478 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2128 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2004 | 280 | 0.010 |
Why?
| | Vascular Resistance | 2 | 1993 | 337 | 0.010 |
Why?
| | Infusions, Intravenous | 2 | 1991 | 371 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2000 | 33 | 0.010 |
Why?
| | Biopsy | 1 | 2003 | 1036 | 0.010 |
Why?
| | Isoflavones | 1 | 1999 | 16 | 0.010 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2000 | 102 | 0.010 |
Why?
| | Vibration | 1 | 1999 | 58 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1999 | 98 | 0.010 |
Why?
| | Hindlimb | 1 | 2000 | 130 | 0.010 |
Why?
| | Organ Size | 1 | 2000 | 434 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 189 | 0.010 |
Why?
| | Uterus | 1 | 2000 | 192 | 0.010 |
Why?
| | Analgesics | 1 | 1999 | 158 | 0.010 |
Why?
| | Acoustic Stimulation | 1 | 1999 | 314 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 102 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 286 | 0.010 |
Why?
| | Creatinine | 1 | 1998 | 425 | 0.010 |
Why?
| | Glucose Transporter Type 4 | 1 | 1996 | 36 | 0.010 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 1993 | 17 | 0.010 |
Why?
| | Citric Acid | 1 | 1993 | 30 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1993 | 173 | 0.010 |
Why?
| | Citrate (si)-Synthase | 1 | 1992 | 46 | 0.010 |
Why?
| | Breath Tests | 1 | 1992 | 82 | 0.010 |
Why?
| | Cell Membrane | 1 | 1996 | 680 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1991 | 71 | 0.010 |
Why?
| | Mitochondria, Muscle | 1 | 1992 | 93 | 0.010 |
Why?
| | Hormones | 1 | 1992 | 132 | 0.010 |
Why?
| | Glucosephosphates | 1 | 1990 | 3 | 0.010 |
Why?
| | Glucose-6-Phosphate | 1 | 1990 | 6 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1991 | 90 | 0.010 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 1990 | 14 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 1990 | 2 | 0.010 |
Why?
| | C-Peptide | 1 | 1991 | 138 | 0.010 |
Why?
| | Lipoproteins, HDL | 1 | 1990 | 75 | 0.010 |
Why?
| | Heart Diseases | 1 | 1993 | 331 | 0.010 |
Why?
| | Fatigue | 1 | 1991 | 294 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1990 | 511 | 0.000 |
Why?
| | Erythrocyte Volume | 1 | 1987 | 4 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1987 | 8 | 0.000 |
Why?
| | Plasma Volume | 1 | 1987 | 13 | 0.000 |
Why?
| | Oxygen | 1 | 1985 | 854 | 0.000 |
Why?
|
|
Kohrt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|